HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R B Livingston Selected Research

Breast Neoplasms (Breast Cancer)

1/2016SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
6/2014Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.
2/2013Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
5/2008Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
9/2001University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity.
1/2001Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
9/2000Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer.
7/2000High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R B Livingston Research Topics

Disease

8Breast Neoplasms (Breast Cancer)
01/2016 - 07/2000
5Neoplasms (Cancer)
05/2008 - 07/2000
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2005 - 10/2000
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
08/2001 - 11/2000
2Inflammatory Breast Neoplasms
01/2016 - 07/2000
1Pathologic Complete Response
01/2016
1Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar)
07/2005
1Cardiotoxicity
09/2001
1Anemia
06/2001
1Fatigue
06/2001

Drug/Important Bio-Agent (IBA)

5Etoposide (VP 16)FDA LinkGeneric
09/2001 - 10/2000
5Cisplatin (Platino)FDA LinkGeneric
08/2001 - 10/2000
4Paclitaxel (Taxol)FDA LinkGeneric
07/2005 - 09/2000
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2016 - 09/2001
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2016 - 06/2014
2Letrozole (Femara)FDA LinkGeneric
02/2013 - 05/2008
1130-nm albumin-bound paclitaxelIBA
01/2016
1Bevacizumab (Avastin)FDA Link
01/2016
1Hormones (Hormone)IBA
01/2016
1Mitoxantrone (Novantrone)FDA LinkGeneric
09/2001
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
08/2001
1Vincristine (Oncovin)FDA LinkGeneric
08/2001
1Vinorelbine (Navelbine)FDA LinkGeneric
07/2001
1Carboplatin (JM8)FDA LinkGeneric
07/2001
1Hemoglobins (Hemoglobin)IBA
06/2001
1Epoetin Alfa (Epogen)FDA Link
06/2001
1Trastuzumab (Herceptin)FDA Link
01/2001
1Pharmaceutical PreparationsIBA
01/2001
1Docetaxel (Taxotere)FDA Link
09/2000
1Taxoids (Taxanes)IBA
09/2000
1Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
07/2000
1Melphalan (Alkeran)FDA LinkGeneric
07/2000
1Busulfan (Busulfex)FDA Link
07/2000

Therapy/Procedure

6Therapeutics
05/2008 - 10/2000
5Drug Therapy (Chemotherapy)
07/2005 - 09/2000
4Radiotherapy
08/2001 - 09/2000
2Neoadjuvant Therapy
01/2016 - 07/2000
1Combination Drug Therapy (Combination Chemotherapy)
10/2000
1Adjuvant Radiotherapy
10/2000
1Pneumonectomy (Lung Volume Reduction)
10/2000